Analyst Reco. Purple Biotech Ltd

Equities

Delayed TEL AVIV STOCK EXCHANGE Other stock markets 13:49:49 12/05/2024 BST			5-day change	1st Jan Change
19.4 ^ILa	-2.51%		-3.96%	-39.18%

04-25	Purple Biotech Ltd.'s Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting	CI
03-14	Purple Biotech Reports Preclinical Proof of Concept for Its Tribody Platform Technology	CI

HC Wainwright Adjusts Price Target on Purple Biotech to $9 From $7, Maintains Buy Rating	31/08/23	MT
JonesTrading Initiates Purple Biotech With Buy Rating, $8 Price Target	21/07/23	MT

No results for this search